Sema4

Sema4 Swab Kit

Newborn screening hasn’t changed much since it was invented in the 1960s, even as science has delivered amazing advances in DNA analysis. Early detection can enable early intervention, but today’s health tests to screen newborns for diseases likely to manifest in childhood are not standardised across the United States. And worse, even the most comprehensive state-mandated testing doesn’t even cover the majority of treatable health conditions that can be detected at that age.

Sema4, a health information company providing advanced genomic testing, today announced the launch of Sema4 Natalis, a supplemental newborn screening test designed to detect 193 childhood-onset diseases or disorders so parents can gain early insight into their baby’s health. This simple genetic test can be performed at home with a gentle cheek swab.

In the United States, newborns are typically screened at the hospital for 34 health conditions on the Recommended Uniform Screening Panel (RUSP), but the selected conditions vary by state and represent only a fraction of the genetic diseases that can manifest in a child’s first decade of life. Advances in DNA analysis have made it possible to detect the presence of far more childhood-onset health conditions long before symptoms appear. As a supplemental test, Sema4 Natalis screens for more than five times the number of genetic diseases than a state’s standard hospital test. For all conditions covered by the test — including atypical epilepsy, spinal muscular atrophy, and childhood cancers, among many others — there are validated medical interventions that may positively influence a baby’s future well-being when introduced early enough. Parents can order Sema4 Natalis online, and all orders will be reviewed and approved by a physician to ensure they are medically appropriate for the child.

Eric Schadt

Eric Schadt, CEO, Sema4

“Until now, families have been likely to be caught off-guard by these early-onset diseases, and prognosis by the time symptoms have manifested is often poor. Thanks to breakthroughs in science and medicine, we can now identify babies at risk for these broader set of diseases and deliver interventions — sometimes as simple as vitamin supplements — in time to make a real difference,” Eric Schadt, PhD, CEO of Sema4, said in a statement. “We believe Sema4 Natalis will give parents the advantage of early insight in support of the care of their children.”

Every Sema4 Natalis order also includes a pharmacogenetic analysis of how a baby is likely to respond to 38 medications commonly prescribed at an early age. This information can help paediatricians guide prescription choice to avoid adverse effects or incorrect doses of medications, including antibiotics.

 

http://bit.ly/2BEXk6d

 

Sema4 Natalis uses advanced DNA sequencing to analyze a baby’s genes with the accuracy of next-generation technology. For children who screen positive for a health condition, genetic counselling is available to the parents and paediatricians to discuss results and help navigate next steps. For parents who missed the opportunity when their babies first came home, the test can be used for children up to 10 years of age.

As noted in its recent comments to the Centers for Medicare and Medicaid Services, the National Organization for Rare Disorders (NORD) finds that “on average, individuals with a rare disease wait seven to 10 years to obtain an accurate diagnosis, leaving many individuals with chronic conditions still waiting for a diagnosis. There are millions of patients in the U.S. who are still undiagnosed, and NGS may be their only hope.”

Sema4 developed Natalis to help address this issue of undiagnosed illness by offering supplemental newborn genetic screening by next-generation DNA sequencing.